Middle aged female rats sustain larger stroke infarction and disability than younger female rats. This older group also shows age-related reduction of insulin like growth factor (IGF)21 in serum and in astrocytes, a cell type necessary for poststroke recovery. To determine the impact of astrocytic IGF-1 for ischemic stroke, these studies tested the hypothesis that gene transfer of IGF-1 to astrocytes will improve stroke outcomes in middle aged female rats. Middle aged (10-12 month old), acyclic female rats were injected with recombinant adeno-associated virus serotype 5 (AAV5) 
The ability of astrocyte's to promote neuroprotection deteriorates with age, when the CNS is more prone to disease pathology particularly stroke (reviewed in Chisholm et al., 2015) . Proliferation of reactive astrocytes after injury is greater (Topp, Faddis, & Vijayan, 1989) and persists longer in the aged brain (Manwani et al., 2011) and results in accelerated glial scar formation in this group (Badan et al., 2003) . Aged reactive astrocytes exhibited an upregulation of genes associated with inflammation and scar formation as compared with adult astrocytes (Buga et al., 2008) . Moreover, aging also affects astrocytic functions critical for stroke recovery such reduced glutamate uptake capacity in aging male rats (Latour et al., 2013) and in middle aged female rats (Lewis, Thomas, Selvamani, & Sohrabji, 2012) . Similarly, while astrocytes normally release a variety of trophic factors that promote neuronal survival and curb CNS degeneration (Ridet, Malhotra, Privat, & Gage, 1997) including insulin like growth factor (IGF)21 and VEGF (Chisholm & Sohrabji, 2016) , these secretions decrease with age (Bhat et al., 2012; Lewis et al., 2012) . The loss of IGF-1 observed in aging astrocytes may result in more severe stroke outcomes observed in middle aged female rats.
IGF-1 plays an important role in development, cell differentiation, neuronal plasticity, and cell survival of the nervous system (Bondy & Cheng, 2004) . IGF-1 also reduces cell death in a variety of experimental neurologic disease models, such Parkinson's (Ayadi, Zigmond, & Smith, 2016 ) traumatic brain injury (Madathil et al., 2013) , and spinal cord injury (Utada et al., 2015) . With age, plasma levels of IGF-1 decrease in many species and in female rats, this decrease is seen as early as middle age, when stroke induced infarction is more severe as compared with young females (Selvamani & Sohrabji, 2010) . Intracerebroventricular (ICV) treatment with IGF-1 poststroke has been reported to decrease infarct volumes in this group (Bake, Selvamani, Cherry, & Sohrabji, 2014) , suggesting that the loss of IGF-1 with age may underlie the more severe stroke outcomes seen in middle-aged females.
In view of the crucial role that astrocytes play in brain injury along with the age-related loss of IGF-1 in middle-aged females, we hypothesize that worse stroke outcomes in this age group is due to reduced availability of astrocytic IGF-1, and that increasing IGF-1 expression in aging astrocytes will improve poststroke outcomes in this group. To test this hypothesis, middle-aged females were injected with recombinant human (h)IGF-1 placed downstream of the glial fibrillary acidic protein (GFAP) promoter and packaged in recombinant adenoassociated virus serotype 5 (AAV5) or with control construct. Following stroke, animals were tested for behavioral impairments, extent of infarction, and neuroinflammation. Our studies show that gene transfer of IGF-1 to astrocytes significantly improves stroke-induced behavioral impairment, without reducing infarct volume, and further reduces neuroinflammation in a model of ischemia reperfusion.
| MATERIALS A ND METHODS

| Animals
Female Sprague Dawley (SD) rats were purchased as retired breeders (10-12 months; weight range 325-350 g) from Envigo Laboratories.
This group met our previously established criteria for reproductive senescence: briefly, at least five successful pregnancies and current acyclicity as defined by vaginal cytology assessed via daily vaginal smears (Jezierski & Sohrabji, 2001 ). All animals were housed in an AAA-LAC-approved facility, maintained on a constant photoperiod (12-hr light/dark cycles), and fed ad libitum with laboratory chow (Harlan Teklad 8604) and water. All animal procedures were performed in accordance with the National Institutes of Health guidelines for the humane care of laboratory animals and were approved by the Institutional Animal Care Committee and the Institutional Biosafety Committee. A total of 112 animals were used in this study.
| Adenovirus constructs
Recombinant adeno associated virus serotype 5 (AAV5) was packaged (Signagen, MD) with the ORF of the human (h)IGF-1 gene downstream of the astrocyte-specific promotor, GFAP (AAV5-GFAP-hIGF-1; see Figure 1 ). The construct also contained the mCherry reporter gene under the CMV minimal promoter to visually detect transfected cells.
The control construct consisted of an identical shuttle vector without the hIGF-1 gene (AAV5-GFAP-control).
| Surgical procedures 2.3.1 | AAV5 injections
Animals were anesthetized (ketamine: 87 mg/kg; xylazine: 13 mg/kg) and placed in a stereotaxic instrument (David Kopf Instruments). Two small holes were drilled into the skull at the following coordinates relative to bregma. For striatum: 10.9 mm anterior posterior, 13.6 mm medial lateral, and a depth of 6.5 mm relative to the dura. For cortex:
10.9 mm anterior posterior, 15.5 mm medial lateral, and a depth of 6.0 mm relative to the dura. In each case, a needle, attached to a Hamilton syringe was lowered to the required depth and AAV5 was delivered slowly to the parenchyma at the rate of 0.02 ml/30 s for a total of 3.5 ml. All animals received one injection each into both the right striatum and right cortex of either the AAV5-GFAP-hIGF-1 construct or the AAV5-GFAP-control construct (Figure 1c ). Two concentrations of AAV5 were used: 2.5 310 11 viral particles (VP)/ml (low dose) and 2.5 3 10 12 (VP)/ ml (high dose). Animals were allowed to recover for 6-8
weeks after injections to allow full integration of the viral particles.
| Middle cerebral artery occlusion
Animals were subjected to middle cerebral artery occlusion (MCAo) via intraluminal suture using our previous procedures (Bake, Okoreeh, Alaniz, & Sohrabji, 2016; Bake et al., 2014) . Briefly, rats were anesthetized with isoflurane and maintained at 378C on heating pads in dorsal recumbency. The neck region was shaved and disinfected and a ventral midline incision was made on the skin. Superficial fascia on the right side of the neck was dissected and the underlying muscles were blunt dissected to expose the right common carotid (CCA), external (ECA), and internal carotid (ICA) arteries. The ECA was separated from the vagus nerve and tied off distally with silk sutures after cauterizing the small branches. Microsurgical clamps were placed on the CCA and ICA.
A loose tie was placed on the ECA, and the free stump of ECA was aligned with the ICA. Twenty-two mm of suture of the appropriate size with a silicon-coated round tip (Doccol Corp., CA) was inserted into ICA lumen through a small nick on the ECA between the two ties. The suture was advanced along the ICA until it reached the origin of the MCA (20 mm of suture) and secured in position with nylon ties. The intraluminal suture was maintained for 90 min and then withdrawn.
Tissue perfusion rate was monitored using Laser-Doppler Flowmetry (Moor Instruments, UK) and the perfusion index was calculated for both ischemic and reperfusion time points. MCAo resulted in an 80%
reduction of blood flow compared with the preocclusion rate and reperfusion restored the perfusion index back to preocclusion levels. In a subset of animals, a permanent (p)MCAo was performed, where the suture was maintained in place for the duration of the experiment. All animals were carefully monitored after surgery and terminated 2 days (early acute phase) or 5 days (late acute phase) after ischemia.
| Confirmation of AAV5 localization
A subset of AAV5-GFAP-control and AAV5-GFAP-hIGF-1 injected animals were terminated 2 days after MCAo and processed for histological analyses to determine uptake of the AAV5 construct. Animals were perfused transcardially with dPBS (Thermo Fisher, MA) followed by 4% paraformaldehyde. The brains were removed from the cranial vault and post fixed in 4% paraformaldehyde overnight at 48C. Brains were transferred to 15% sucrose overnight at 48C and subsequently embedded in RichardAllan Scientific Neg 50 TM (ThermoFisher, MA) and then sectioned (30 microns) using a cryostat (Microm HM 550, ThermoFisher, MA).
Sections were collected on superfrost slides (Thermo Scientific, MA), air dried, and fixed with 4% paraformaldehyde for 30 min and blocked in blocking buffer (2% normal goat serum or rabbit serum and 0.2% triton X-100 in dPBS) for 1 hr at room temperature. Sections were then incubated with primary antibodies for hIGF-1 (Sigma, 1:80 dilution) or GFAP (Sigma, CA, 1:80 dilution), (overnight 16 hr) followed by a 1 hr incubation with fluorescent-labeled secondary antibodies (Oregon green 488 donkey anti-goat, 1:500 dilution and Oregon green 488 goat anti-rabbit, 1:500 dilution, respectively). Fluorescent labeling was visualized on the Olympus FSX100 Bio Imaging Navigator and captured digitally by FSX-BSW software (Waltham, MA).
| Infarct Analysis
Infarct volume was measured using our previous published procedures (Selvamani & Sohrabji, 2010) . Two or 5 days after MCAo rats were deeply anesthetized and decapitated, and the brain was rapidly removed. Coronal slices (2 mm thick) between 22.00 mm and 14.00 mm from bregma were sectioned in an adult rat brain slicer matrix (Roboz Surgicals, Gaithersburg, MD) and incubated in a 2% Triphenyl tetrazolium chloride (TTC) solution at 378C for 20 min. Stained slices were photographed using an Olympus E950 digital camera attached to a dissecting microscope Infarct volume was determined from digitized images using the Quantity One software package (BioRad, CA). Typically, 3 such slices were used for analysis. The area of the cortical and striatal infarct was measured separately in all slices, and the area of the entire contralateral hemisphere was also measured.
The volume of the infarct was normalized to the volume of the contralateral (nonoccluded) hemisphere. To ensure reliable and consistent detection of the infarct zone, images were digitally converted to black and white and magnified. Images were coded and the sections were analyzed by an investigator blind to the code (AO).
| Behavioral analysis
Animals were evaluated for sensorimotor performance pre-and poststroke using the vibrissae evoked forelimb placing task (Woodlee et al., 2005) as described in (Selvamani & Sohrabji, 2010) . Animals were subject to same-side placing trials and cross-midline placing trials elicited by stimulating the ipsi-and contra-lesional vibrissae.
| Same side placing test
The animal was gently held such that all four limbs were free to move.
The animal's ipsi-lesional vibrissae were brushed against the edge of a 
| Motility Test
Animals were placed on an open surface and their movement was monitored. Animals that walked normally received a score of 0. Animal with any difficulties were given a 1. Deficits includes immobility, inability to walk straight, circling and falling down (Normal 5 0, maximum 5 1).
| Grasping
Animals were suspended by its forelimbs on a small beam. Grasping ability and forelimb strength were assessed. Animals that grasped the beam with both paws were given a 0. Animals that grasped only with the ipsi-lesional paw were given a 1. Animals that could not grasp the beam were given a 2. (Normal 5 0, maximum 5 2).
| Righting Reflex
To test the righting reflex, rats were placed on their backs. If the animal took less than 3 s to right itself, the animal received a score of 0. An animal that took longer than 3 s or was not able to perform the task was given a score of 1. (Normal 5 0, maximum 5 1)
| Forepaw disability
Animals were placed a cylinder and observed. Animals that were able to rear and make contact with the wall of the cylinder with both paws were scored as 0. Animals that were only able to consistently place the ipsi-lesional paw were scored 1. Animals did not place either paw in 2 min, were scored as 2. (Normal 5 0, maximum 5 2)
| Circling
Animals with no circling behavior were given a 0. Animals with an inability to walk straight and a flexion of the forelimb toward the paretic side after suspension by the tail were given a score of 1. Animals with constant circling to the paretic side were given a score of 2.
Animals with constant circling to the paretic side which a slight tendency to fall were given a score of 3. Animals that were barreling were given a score of 4. Animals that were comatose were given a score of 5. (Normal 5 0, maximum 5 5) Following a 2 min incubation at RT, samples were centrifuged at 12,000 3 g for 15 min at 48C. The aqueous phase was then transferred to a fresh tube and mixed with ethanol (1.5 vol). The sample was then loaded on to an RNeasy Mini Spin Column and centrifuged for 30 s at RT, 13,000 3 g. After sequential washes in RWT and RPE buffers, the columns were transferred to a fresh tube and RNA eluted with 50 ll of DNase/RNase-free water. Sample purity was assessed by Nanodrop technology and a ratio of 1.8 was considered acceptable. Samples were stored at 2808C until use.
| Real-time RT-PCR
mRNA expression for specific genes in AAV5-GFAP-control and AAV5-GFAP-hIGF-1 -treated animals was assessed using real-time qRT-PCR. 200 ng of purified total RNA was used to generate cDNA, using a Universal cDNA Synthesis Kit (Exiqon, Denmark) according to the manufacturer's protocol. 1 ml of cDNA samples were used as a PCR reaction template in a 10 ml PCR reaction. PCR reactions were run in triplicate on an Applied Biosystems 7900HT real-time PCR instrument (Applied Biosystems, CA) using a SYBR green-based real-time PCR reaction kit (Exiqon, Denmark). 18s mRNA was used as a normalization control. Specificity of the amplification was evaluated by thermal stability analysis of the amplicon. Individual and reference gene primer sets (Integrated DNA Technologies, Coralville, IA) are listed in the Table 1 .
| Cell preparation
Animals were anesthetized (xylazine and ketamine i.p.) and perfused intracardially with 100 ml of cold 1X PBS. Ischemic and nonischemic hemispheres were collected and minced using a blade. Following a wash with X-VIVO 15 (Lonza, TX), a chemically-defined, serum free hematopoetic medium, tissues were first enzymatically dissociated using the Neural Dissociation Kit P (Miltenyi Biotech, CA) and then transferred to a glass Dounce homogenizer and mechanically dissociated. The suspension was then filtered through a 30 lm strainer, and washed twice in X-VIVO 15.
| For astrocyte separation
Cells were incubated with anti-GLAST antibody (1:5) for 10 min.
GLAST was selected as a marker because it is an astrocyte-specific, membrane-associated protein and results in a virtually pure astrocyte population (Chisholm et al., 2015) . Cells were then washed and spun at 300 3 g for 10 min followed by incubation with biotin microbeads for 15 min. Cells were subsequently washed, spun (300 3 g; 10 min), and resuspended in 2 ml of buffer and passed through LS columns. The columns were washed with buffer (33 3 ml), and the flow-through discarded. The LS column was then removed from the magnetic stand.
Astrocytes were then eluted from the column and washed in cold dPBS.
| For flow cytometry of immune cells
The cell pellet retrieved was resuspended in 6 ml of X-VIVO 15, and applied to an Opti-Prep gradient (Axis Shield, Olso, Norway). The gradient was composed of four 1-ml layers of Opti-prep diluted in X-VIVO 15, arranged in the following order (from bottom to top): 35%, 25%, 20%, and 15%. The 10 ml tube containing the cell suspension and gradient was centrifuged at 1900 rpm for 15 min at 208C with low acceleration and no brake. Following centrifugation, the top 7 ml of solution containing myelin and debris, was aspirated and discarded. The remaining 3 ml, containing inflammatory cells and glia, was washed twice in X- ng/ml) using KC3 software (Bio-Tek), and sample measurements were interpolated from standard curves. The intraassay coefficient of variation was 1.30%.
| Multiplex Cytokine Kit
Tissue expression for a panel of cytokine/chemokine was measured in the ischemic and nonischemic hemisphere and serum of rAAV5-GFAPhIGF-1 and rAAV5-GFAP-control animals, using a multiplexed magnetic bead immunoassay (Milipore Corp., MA) following manufacturer's instructions. Briefly, the filter plate was blocked with assay buffer for 10 min and decanted. Standards and samples was added into appropriate wells, followed by addition of premixed beads and incubated for 2 hr at room temperature on a plate shaker. Wells were washed 2 times, 
| Statistical analyses
Group size was determined using power analyses. Power analyses was computed based on effect sizes seen in previous data and pilot studies. Expression of hIGF-1 was further confirmed by qRT-PCR in whole brain homogenates and astrocyte homogenates. Astrocytes were collected by GLAST-positive selection by magnetic beads, using our previous procedures that results in a virtually pure astrocyte population (Chisholm et al., 2015) . As expected, hIGF-1 was undetectable by qRT-PCR in whole hemisphere homogenates ( Figure 2di ) and astrocytes homogenates ( Figure 2dii ) from either the ischemic or nonischemic hemisphere of animals injected with rAAV5-GFAP-control. In contrast, hIGF-1 was highly expressed in whole brain and astrocyte homogenates of the ischemic hemisphere of animals that were injected with AAV-GFAP-hIGF-1, with virtually no hIGF-1 gene expression in the nonischemic hemisphere. There was no difference in the amount of rat IGF-1 expression in tissue lysates and astrocytes regardless of hemisphere or treatment (Figure 2diii and 2Div) . qRT-PCR of astrocyte homogenates used in these analyses show strong expression of GFAP, and virtually undetectable levels of PECAM (endothelial cell marker) and Iba1 (microglial specific marker) (Figure 2e ), indicating an enriched astrocyte population.
| R E S U LTS
| Characterization of AAV5 Integration
| Postischemic Survival
Two doses of AAV5-GFAP-Control and AAV5-GFAP-hIGF-1 were injected into the striatum and cortex, a low dose of 2.5 3 10 11 VP/ml and a high dose of 2.5 3 10 12 VP/ml. After 6-8 weeks postinjection, all animals were subject to MCAo. In the high dose treatment, poststroke mortality was higher in animals injected with the AAV5-GFAP-control as compared with AAV5-GFAP-hIGF-1 treated animals (p < .0001; Figure 3a) . High dose AAV5-GFAP-control animals did not survive more than 24 hours poststroke, while high dose AAV5-GFAP-hIGF-1 treated animals survived 5 days, the predetermined termination point for this study.
Animals that received the low dose AAV5 treatment did not show any differences in poststroke mortality (Figure 3b ; p 5 .8311). Both rAAV5-GFAP-control and AAV5-GFAP-hIGF-1 groups survived until the predetermined termination point of the study at 5 days. Therefore, all subsequent studies were performed with the low dose AAV5.
| Physiological measures affected by MCAo at the early acute period (2 days) poststroke
Animals injected with AAV5-GFAP-control and rAAV5-GFAP-hIGF-1 were subject to ischemic stroke for 90 min followed by reperfusion.
Both groups experienced approximately 10% weight loss at 2 days poststroke, which is commonly seen after stroke, however there was no difference in the extent of weight loss between the two groups 
| Poststroke sensory-motor behavioral outcomes
To assess the effect of AAV5 treatment on sensory motor function poststroke, the vibrissae evoked-forelimb placing task performance was assessed at 2 days (early acute phase) and 5 days (late acute phase) after MCAo. Consistent with other reports, sensory motor performance improved as animal progressed from the acute phase to the late phase. For the rAAV5-GFAP-control group, there was no response (NR) to either the same side or cross-midline test on the side contralateral to the ischemic side (contralesional) during the early acute phase (Figure 5ai ). In the AAV5-GFAP-hIGF-1 group, during the early acute phase (2d poststroke), poststroke performance was impaired compared with the prestroke performance, however animals in this group were still able to maintain about 45% of their prestroke responses to the vibrissae stimulation, unlike the AAV5-GFAP-Control group (F (3,24) 53.44; p 5 .0359; Figure 5ai ).
Similarly, on the ipsilesional side for the early acute phase, AAV5-GFAP-control had no responses to the same side test, while the AAV5-GFAP-hIGF-1 group maintained 40% of their prestroke responses (F (3, 24) 5 13.84; p < .0001), although these were lower than the prestroke levels (F (1, 24) 5 50.28; p < .0001; Figure 5aii ). No loss of response was seen on the cross-midline task on the ipsilesional side. During the late acute phase (5 days poststroke), improvement was noted in both groups, however performance in the AAV5-GFAPcontrol group was significantly worse than prestroke levels (F (1, 14) 515.79; p 5 .0014). Specifically, AAV5-GFAP-Control animals had lower responses on the same side (54%, p 5 .0294) and cross midline (42%, p 5 .0059) task on the paw contralateral to the infarct ( Figure   5bi ). In contrast, performance of the AAV5-GFAP-hIGF-1 group was statistically no different from the prestroke performance (p 5 .9; Figure   5bi and 5 bii), indicating an improved rate of recovery.
| Blood brain barrier permeability
Circulating levels of GFAP were analyzed as a surrogate measure of blood brain barrier permeability function (Marchi et al., 2004 ) from serum samples collected prestroke, during the early acute and late acute phases of stroke. As shown in Figure 6a , GFAP was detected in all samples, however there was a main effect of stroke (pre and poststroke) and treatment (AAV-GFAP-Control vs. AAV-GFAP-IGF-1).
GFAP levels were significantly elevated in both groups after stroke (F (1,27) 5 7.32, p < .05), and also significantly elevated by treatment (F (1,27) 5 7.72, p < .05) such that animals with AAV-GFAP-hIGF-1 had significantly lower levels of GFAP. Planned comparisons showed that while the groups were no different at baseline, the AAV5-GFAP-hIGF-1 group had almost 50% lower levels of circulating GFAP as compared with the AAV5-GFAP-control group, indicative of decreased blood brain barrier permeability.
3.6 | Stroke-induced inflammation
| Serum Cytokines and Chemokines
A panel of cytokines and chemokines were examined in serum at 2 days after MCAo for AAV5 treated animals. Almost all cytokines and chemokines were elevated after ischemia (Supporting Information   Table 1 ), while a subset was also affected by IGF-1 gene transfer. Compared with the rAAV5-control group (Figure 6b) , the AAV5-GFAPhIGF-1 groups showed elevated levels of G-CSF (main effect of treatment, p 5 .0048, and stroke, p 5 .0331), IL-4 (main effect of treatment, p 5 .0332, and stroke, p 5 .0005), IL-5 (main effect of treatment, p 5 .0216, and stroke, p 5 .0004), Eotaxin (main effect of treatment, p 5 .0160, and stroke, p 5 .0011), and IL12-P70 (main effect of treatment, p 5 .0232, and stroke, p < .0001). hemisphere of AAV5-GFAP-hIGF-1 treated animals as compared with AAV5-GFAP-control animals (p 5 .0219; Figure 7c ).
| Trafficking of peripheral immune cells
In the case of infiltrating macrophages, identified by CD45 high / CD11b/Iba1, there were no differences in the proportion of these invading cells in the AAV5-GFAP-control and AAV5-GFAP-hIGF-1 groups (p 5 .2280; Figure 8a ). However, infiltrating macrophages differed in the extent of M1 and M2 cohorts seen in each group. As shown in Figure 8b , the proportion of infiltrating macrophages labeled with CD68/CD86 (M1 phenotype) was decreased by 62% in AAV5-GFAP-IGF-1 treated animals as compared with AAV5-GFAP-control treated animals (p 5 .0485). In contrast, the proportion of infiltrating macrophages labeled with CD163/CD206 (M2 phenotype) was increased by 57% in AAV5-GFAP-hIGF-1 treated animals as compared with AAV5-GFAP-control treated animals (p 5 .0248; Figure 8c ).
There were no group differences in the proportion of resident microglia, identified by CD45 l 8 w /CD11b/Iba1 (data not shown).
3.7 | Impact of rAAV5-GFAP-hIGF-1 in a permanent ischemia model
In view of the perivascular location of rAAV-GFAP-hIGF-1 cells, we next determined whether replenishing astrocytic IGF-1 would be effective in a permanent ischemic model (i.e., no reperfusion). As shown in Figure 9 , AAV5-GFAP-hIGF-1 treatment had no effect on any of the measures tested. Similar to the transient MCAo, animals lost weight after stroke, and there were no group effects on weight loss ( Figure   9a ). In case of the neurological score, AAV5-GFAP-control animals were significantly impaired after permanent MCAo (Figure 9b ), averaging a score of 4 for both groups, similar to the deficiency seen in the transient MCAo for AAV5-GFAP-control group (compare with Figure   4c ). However, in the pMCAo condition, AAV5-GFAP-hIGF-1 treatment had no effect on the neurological score (p 5 .9769). Infarct volume (Figure 9c ; p 5 .7721) was also no different between the two groups, although mean infarct volume was much higher in this model than the transient ischemic model (Figure 4d ). The vibrissae evoked forelimb placing task showed that both groups were severely impaired ( Figure   9di and 9dii), and performance was not improved by AAV5-GFAPhIGF-1. Overall, AAV5-GFAP-hIGF-1 had no protective effect on the permanent MCAo model.
| DISCUSSION
These data support the hypothesis that elevating IGF-1 expression in astrocytes significantly improves stroke outcomes after transient ischemia-reperfusion in middle-aged female SD rats. AAV5 mediatedexpression of hIGF-1 in astrocytes reduced stroke-induced motor while controls experienced a decrease in systolic blood pressure after stroke, which is associated with poorer clinical outcomes and increased mortality in stroke patients (Lin, Ovbiagele, Markovic, & Towfighi, 2015; Okin, Kjeldsen, & Devereux, 2015) especially in the acute period of stroke (Wohlfahrt et al., 2015) . These novel findings are in accordance with a growing body of evidence that functional modifications of astrocytes yields major benefits for neurodegenerative diseases (Bajenaru, Zhu, Hedrick, Donahoe, Parada, & Gutmann, 2002; Furman et al., 2012 Furman et al., , 2016 . tive to the anti-inflammatory cytokine IL-10, which results in prolonged neuroinflammation due to persistent microglial activation (Norden, Trojanowski, Walker, & Godbout, 2016) . Our previous studies show that, compared with astrocytes from younger female rats, astrocytes from middle-aged females have significantly reduced capacity for glutamate clearance, elevated expression of chemokines and increased ability to recruit PBMC in cocultures (Lewis et al., 2012) . More recent studies
show that astrocytes from middle aged females have epigenetic modifications that cause transcriptional repression (Chisholm et al., 2015) .
This decline in astrocytic functional capacity coincides with an increase in infarct volumes and worsening poststroke recovery in our model.
Whether astrocyte dysfunction is the cause or the result of disease
progression has yet to be elucidated. Nevertheless, astrocyte replacement by neural progenitor cells and glial-restricted precursors is reported to have some benefit in acute injury models such as spinal cord injury (Haas & Fischer, 2013; van Gorp et al., 2013) .
Targeted modification of astrocyte proteins has been used in several neural injury models with success. In Huntington's disease, AAV2/ 5 mediated restoration of Kir4.1, a rectifying potassium channel, in striatal astrocytes increased longevity and improved motor performance on the rotorad test, footprint analysis, and paw clasp test (Dvorzhak et al., 2016) . In spinal cord injury, AAV8-mediated overexpression of Glutamate transporter 1, a protein found primarily in astrocytes, increased diaphragm dysfunction, affected breathing, and increased forelimb dysfunction six weeks after contusion (Li et al., 2014) . In hippocampal ischemic injury, heat shock protein (Hsp)70 or superoxide dismutase (SOD) targeted for expression in astrocytes reduced cell death (Xu et al., 2010) in vivo, while virally-mediated astrocyte specific expression of the excitatory amino acid transporter (EEAT2) decreased cell death in hippocampal cultures exposed to moderate oxygen glucose deprivation (OGD) (Weller et al., 2008) . Interestingly, enhanced expression of EEAT2 was only neuroprotective against moderate levels of OGD but not severe OGD (Weller et al., 2008) . This was also seen in the present study where AAV5-mediated IGF-1 in astrocytes improved sensory motor function after stroke in transient MCA ( Figure   5 ) but not permanent MCAo, which results in a much larger infarct volume ( Figure 9 ) and is considered a more severe ischemic injury. In transient focal ischemia, suppression of CD38 in astrocytes reduced transfer of mitochondria, resulting in worse neurological outcomes. (Hayakawa et al., 2016) . The unique finding of this study is that while non-cell specific viral-mediated transfer of IGF-1 either prior (Zhu et al., 2008) or after (Zhu et al., 2009 ) MCAo promotes neovascularization and neurogenesis, the present study is first demonstration that astrocyte targeted IGF-1 improves motor outcomes poststroke.
Surprisingly, while virally-mediated increase in astrocyte IGF-1 improved neurological scores and sensory motor performance and barrier function, it did not lead to reduction of infarct volume. While some studies have shown a significant correlation between increased infarct volume and worse neurological scores and motor impairment (Rogers, Campbell, Stretton, & Mackay, 1997) , other studies showed no correlation between behavioral impairment and infarct volume (Wahl, Allix, Plotkine, & Boulu, 1992) . Clinically, infarct volumes are not the strongest predictor of long-term prognosis unless combined with NIHSS scores (Baird et al., 2001) , as well as involvement of white matter tracts and cerebral blood supply (Heiss & Kidwell, 2014) . Furthermore, Iba1/CD68/CD86 stained cells) in AAV5-GFAP-control and AAV5-GFAP-hIGF-1 treated animals (*: p 5 .0485) and infiltrating M2 macrophages (CD45 high /CD11b/Iba1/CD163/CD206) (*: p 5 .0248). All graphs represent mean 6 SEM, n 5 5-6 in each group several other growth factors therapies also improve behavior independent of infarct volume. In SD rats, fibroblast growth factor treatment initiated 1 day after MCAo improved behavioral recovery but had no effect on infarct volume (Kawamata, Alexis, Dietrich, & Finklestein, 1996) . Similarly, rats infused with brain-derived neurotrophic factor after MCAo showed less functional deficit at 28 days after treatment than controls but lesion size measured by T2-MRI did not show differences at 7 and 28 days (Ramos-Cejudo et al., 2015) . Additionally, blocking ephrin-A5 signaling, an important pathway for axonal sprouting in premotor and prefrontal motor circuits, in reactive astrocytes after MCAo also improved motor function recovery without a significant change in infarct volume (Overman et al., 2012) .
The current studies also reveal a clear difference between the neuroprotective effects of intracerebroventricular (ICV) infusions of hIGF-1 versus AAV5-mediated astrocyte expression of hIGF-1. In middleaged SD rats, intracerebroventricular (ICV) delivery of hIGF-1 after stroke significantly decreases infarct volume and reduces blood brain barrier permeability (Bake et al., 2014) . Furthermore, ICV hIGF-1 treatment decreased trafficking of CD41 cells and T regulatory cells into the ischemic hemisphere, consistent with the idea that IGF-1 reduces hyperpermeability at the blood brain barrier (Bake et al., 2016 ). In contrast, astrocyte-derived hIGF-1, did not improve infarct volume although barrier properties were improved as evidenced by serum GFAP levels. Furthermore, astrocyte hIGF-1 did not reduce overall immune trafficking into the ischemic hemisphere, but altered the cohort of immune subtypes. Thus, while there was no difference in the proportion of M1/M2 phenotype resident microglia, infiltrating regulatory T cells and infiltrating M2 macrophages were elevated, indicating that astrocyte-derived hIGF-1 altered immune cell transmigration to favor neurosupportive and anti-inflammatory cells (Li et al., 2013; Liesz et al. 2015; Won et al., 2015) . The difference between the actions of ICV delivery of IGF-1 versus astrocyte mediated hIGF-1 could be due to differences in the amount of IGF-1 available via each method or due to the fact that virally-induced astrocyte hIGF-1 constitutes a "pretreatment" while ICV-hIGF-1 is a poststroke treatment. Overall, our previous and current data support the hypothesis that the poorer Neurological score assessed 2days after stroke in AAV5-GFAP-control and AAV5-GFAP-hIGF-1 treated animals. (c) Infarct volume measured 5d after stroke in AAV5-GFAP-control and AAV5-GFAP-hIGF-1 treated animals. (di and dii) Sensory-motor performance measured by vibrissae evoked forelimb placing task in AAV5-GFAP-control and AAV5-GFAP-hIGF-1 treated animals. All graphs represent mean 6 SEM. n 5 5-6 in each group. No significant differences were seen in any of these measures stroke outcomes in older females are associated with age-related decreases in this peptide hormone.
Despite its central location, AAV5-mediated astrocyte hIGF-1 expression has striking effects on the peripheral physiological milieu, as seen by regulation of peripheral cytokines as well as maintenance of systolic blood pressure poststoke. Astrocytic hIGF-1 elevated circulating levels of granulocyte colony-stimulating factor (GCSF), which is reported to be neuroprotective (Bath & Sprigg, 2007; Fan et al., 2015; Shin & Cho, 2016) , as well as IL-4 and IL-5, which are associated with the Th2 immune response and correlates with reduction in infarct volume (Luo et al., 2015) . Peripheral inflammation in stroke patients, usually caused by infection, worsens stroke outcomes (Grau et al., 1999) .
LPS treatment after stroke, for example, increases macrophage infiltration and caused a prolonged impairment of hindlimb function (Langdon, MacLellan, & Corbett, 2010) . Thus behavioral improvement seen in AAV-GFAP-hIGF-1 infected animals may be mechanistically linked to a modification of the inflammatory environment.
Astrocytes are the most abundant cell in the brain, outnumbering neurons by at least five to one (Cotrina & Nedergaard, 2002; Sofroniew & Vinters, 2010) . 
